r/valueinvesting
McKesson ($MCK) 深度分析：20% 的恐慌与结构性安全边际
MCK 20%的下跌是买入良机，因其具备寡头护城河、积极回购及向高利润肿瘤业务转型。
- 在药品分销领域拥有理性寡头垄断护城河，客户转换成本高。
- 轻资产模式产生强劲自由现金流，配合积极回购，20年内流通股减少超60%。
- 战略转向高利润率的肿瘤和多专科业务，同时剥离低利润资产。
大家好，
在麦凯恩公司（$MCK）从峰值回落约20%后，我想快速分享一下我对它的基本面观点。我在帖子底部附上了链接，方便有兴趣深入了解的朋友阅读。股价从接近1000美元跌至约740美元，主要原因是2026财年第四季度营收未达预期。然而，深入分析后会发现，这家长期复利增长公司的结构性逻辑依然非常稳固。
以下是价值主张的核心支柱：
- 理性寡头护城河
麦凯恩、Cencora 和卡迪纳尔健康（Cardinal Health）共同掌控了美国药品分销市场的绝大部分份额。它们对医院网络和药房的价值主张在于绝对可靠的供应链以及营运资金优化。社区药店无法承受在资产负债表上持有数百万美元的库存；麦凯恩负责物流，从而创造了巨大的客户转换成本。
- 轻资产资本配置与自我蚕食
尽管利润率极薄（约1.5%的运营利润率），但MCK的商业模式极为轻资产，在2026财年产生了54亿美元的自由现金流。管理层的资本配置策略与股东利益完全一致，薪酬直接与ROIC和调整后每股收益挂钩。他们不通过低回报项目扩张帝国，而是积极回购股票。过去20年间，麦凯恩已将流通股数量减少了超过60%，为每股指标创造了永久性的助推力。
- 高毛利业务转型
市场仍把MCK当作一家停滞的老旧分销商，但管理层正积极剥离低毛利、非核心资产（如最近的欧洲资产出售，以及出售Rexall/Well.ca）。他们正将资本转向肿瘤学和多专科业务板块，该板块在2026财年实现收入增长31%，运营利润增长53%。这一板块的运营利润率高达2.27%，是其核心药品分销业务的两倍。
- 估值与安全边际
采用极其保守的假设——未来四年增长完全停滞，第四年降至2%，第五年归零，终端增长率为0%——我的DCF模型显示，麦凯恩的保守内在价值为每股885美元（相比最坏情况仍有18%的上行空间）。
若将终端增长率调至更现实但仍非常保守的2%（与长期通胀目标一致），内在价值跃升至每股1275美元，对应70%的上行空间。
总结：
• 有利因素：美国老龄化人口带来的结构性需求，以及GLP-1激动剂带来的巨大销量加速。
• ROIC：去年达到惊人的70%。
• 股东回报：董事会刚刚在第四季度末批准了一项新的50亿美元股票回购计划。
我很想听听大家对麦凯恩与卡迪纳尔/Cencora之间竞争格局的看法，以及认为近期的营收不及预期是结构性问题，还是只是暂时的噪音？
如果你想阅读完整分析，或更深入研究这家公司，可以在这里查看我的深度剖析：https://mulberryfinancial.substack.com/p/mckesson-mck-stock-analysis-deep-dive-2026?r=4af6n2
I held Cencora back when it was still AmerisourceBergen for a couple years, and the thing that finally clicked is that the revenue line on these is basically theater. They run on roughly 1% operating margins, so a headline beat or miss on sales tells you almost nothing. What actually moved the stock every quarter was segment operating profit and whether a big pharmacy contract was coming up for renewal. Once I stopped reacting to the topline, the whole sector got a lot easier to sit through drops like this 20% one.
Great point, thanks for the insight.
I’m looking to make an entry in Cencora, any recommendations if this is a good or bad idea? I like the price from its all time
Highs.
This is a business model that can evaporate at any moment, literally with the stroke of a pen. I’m heavily in favour of pharma when it comes to the drug price ‘issue’ and I believe their arguments against the big PBMs are much more convincing, and politicians are far more receptive to such arguments than those coming out the managed care/PBM lobby base
Respectfully, it is not true that this business model could evaporate at any moment, literally with the stroke of a pen. I spoke with numerous pharmacy professionals while writing this, and all I took awqy from those meetings is that it would be very, very difficult, if not impossible, for this business model to "evaporate".
The opioid litigation against all 3 companies has been settled. Agree with you that the business model can’t just evaporate. Thank You for the worst case scenario terminal growth information. I see cardinal health investors rotating into McKesson because CAH is at an all time high right now.
Great points. I have held mck for years. Buying as much as I can in the $750 range
The top-line miss being treated as structural is the part that gets me. When your business model is built around pharmaceutical volume throughput and an aging population, a single quarter's revenue shortfall looks a lot more like procurement timing or formulary shifts than any kind of demand destruction.
The oncology pivot is genuinely the most interesting piece of this thesis to me. 53% operating profit growth in that segment while the market is pricing it like a plain distributor is a weird disconnect. The margin differential between oncology and core distribution is small in absolute terms but the trajectory is what matters, and management seems to be allocating capital accordingly.
The 60% share count reduction over 20 years is the kind of stat that sounds boring until you actually model what that does to per-share earnings over a full cycle. Most people skip past it and anchor on total revenue or headline margins, which is exactly why the market keeps misreading capital-light compounders like this.
The ROIC at 70% is the number I'd push back on a little though. Not that it's wrong, but that level tends to attract regulatory scrutiny in healthcare distribution eventually, and the oligopoly structure has been on policy radar on and off for years. Worth keeping an eye on even if it's not an immediate risk.
Cardinal health and cencora missed badly on revenue last quarter also so it was an industry wide issue. What surprises me is how CAH went from a $181 low after earnings all the way to all time highs at $234 so fast. McKesson and cencora are more undervalued than CAH right now.
Great points thanks for the insight.